Patil Neena M 4
4 · Jazz Pharmaceuticals plc · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Jazz Pharmaceuticals EVP Neena Patil Exercises Options, Sells Shares
What Happened
Neena M. Patil, EVP and Chief Legal Officer of Jazz Pharmaceuticals, exercised stock options and sold common shares on February 26, 2026. She exercised a total of 51,000 option shares (two strike prices: $113.10 and $137.12) for aggregate exercise cost of about $6.49M and received 10,079 restricted stock units (RSUs). In multiple open-market transactions the same day she sold 55,600 shares for total proceeds of approximately $10.65M — producing roughly $4.16M in proceeds after accounting for the exercise costs.
Key Details
- Transaction date: February 26, 2026; Form 4 filed March 2, 2026 (filed within the standard two business-day window).
- Options exercised (code M): 51,000 shares at $113.10 and $137.12 (total exercise cost ≈ $6.49M).
- Open-market sales (code S): 55,600 shares sold in multiple trades for total proceeds ≈ $10.65M (weighted-average prices reported; per-footnotes sale prices ranged roughly $189.39–$193.84).
- Award/grant (code A): 10,079 RSUs granted (vest beginning March 5, 2026 per footnote).
- Filing shows several derivative disposals reported at $0 (reported shares withheld/settled); such $0 entries commonly reflect share withholding to cover exercise costs or taxes.
- No 10b5-1 plan or late filing flag is disclosed in the provided excerpt.
Context
This was an exercise-and-sell sequence (often called a cashless exercise): the insider exercised options and sold shares the same day. Exercises followed by same-day sales are routine for option holders and typically reflect option liquidity or tax/covering actions rather than an outright directional market bet. The RSU grant is a separate compensation award subject to vesting (see footnote for schedule).
Insider Transaction Report
Form 4
Patil Neena M
EVP & Chief Legal Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2026-02-26$113.10/sh+20,125$2,276,138→ 73,464 total - Sale
Ordinary Shares
[F1]2026-02-26$192.53/sh−16,602$3,196,335→ 56,862 total - Exercise/Conversion
Ordinary Shares
2026-02-26$113.10/sh+875$98,963→ 57,737 total - Sale
Ordinary Shares
[F2]2026-02-26$192.07/sh−875$168,057→ 56,862 total - Exercise/Conversion
Ordinary Shares
2026-02-26$137.12/sh+27,084$3,713,758→ 83,946 total - Sale
Ordinary Shares
[F3]2026-02-26$190.28/sh−15,555$2,959,807→ 68,391 total - Exercise/Conversion
Ordinary Shares
2026-02-26$137.12/sh+2,916$399,842→ 71,307 total - Sale
Ordinary Shares
[F4]2026-02-26$189.81/sh−2,916$553,491→ 68,391 total - Award
Ordinary Shares
[F5]2026-02-26+10,079→ 78,470 total - Sale
Ordinary Shares
[F6]2026-02-26$191.65/sh−11,529$2,209,481→ 66,941 total - Sale
Ordinary Shares
[F7]2026-02-26$193.58/sh−3,523$681,993→ 63,418 total - Sale
Ordinary Shares
[F8]2026-02-26$190.00/sh−1,061$201,594→ 62,357 total - Sale
Ordinary Shares
[F9]2026-02-26$190.80/sh−549$104,747→ 61,808 total - Sale
Ordinary Shares
[F10]2026-02-26$191.88/sh−1,784$342,312→ 60,024 total - Sale
Ordinary Shares
[F11]2026-02-26$192.79/sh−1,009$194,527→ 59,015 total - Sale
Ordinary Shares
[F12]2026-02-26$193.60/sh−197$38,139→ 58,818 total - Exercise/Conversion
Incentive Stock Option (right to buy)
[F13]2026-02-26−875→ 0 totalExercise: $113.10Exp: 2030-02-26→ Ordinary Shares (875 underlying) - Exercise/Conversion
Incentive Stock Option (right to buy)
[F14]2026-02-26−2,916→ 0 totalExercise: $137.12Exp: 2029-08-07→ Ordinary Shares (2,916 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F13]2026-02-26−20,125→ 0 totalExercise: $113.10Exp: 2030-02-26→ Ordinary Shares (20,125 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F14]2026-02-26−27,084→ 0 totalExercise: $137.12Exp: 2029-08-07→ Ordinary Shares (27,084 underlying)
Footnotes (14)
- [F1]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.1100 to $193.0100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F10]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.4750 to $192.4300. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F11]Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $192.4600 to $193.4500. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F12]Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $193.5300 to $193.6700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F13]These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.
- [F14]These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of July 29, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.
- [F2]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $192.0600 to $192.1100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F3]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.9150 to $190.9000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F4]Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $189.7300 to $189.9150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F5]These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
- [F6]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $191.3200 to $192.0600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F7]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $193.2900 to $193.8400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F8]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.395 to $190.3700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F9]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.4100 to $191.2150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Signature
By: /s/Paz Dizon, as attorney in fact For: Neena Patil|2026-03-02